A5072432144- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- COVID-19 Clinical Research Studies
- COVID-19 and healthcare impacts
- Autoimmune and Inflammatory Disorders
- Diverticular Disease and Complications
- Diagnosis and treatment of tuberculosis
- Chronic Lymphocytic Leukemia Research
- SARS-CoV-2 and COVID-19 Research
- Psoriasis: Treatment and Pathogenesis
- Biosimilars and Bioanalytical Methods
- Helicobacter pylori-related gastroenterology studies
- Gastrointestinal disorders and treatments
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders Research
- Tuberculosis Research and Epidemiology
- Mycobacterium research and diagnosis
- Veterinary medicine and infectious diseases
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
- Celiac Disease Research and Management
- Anorectal Disease Treatments and Outcomes
- Pregnancy and Medication Impact
- Health Systems, Economic Evaluations, Quality of Life
Hospital Israelita Albert Einstein
2014-2025
Pan American Health Organization (Brasil)
2024-2025
Hospital São Paulo
2014-2022
Instituto de Saúde
2022
Ministerio de Ciencia, Tecnología y Medio Ambiente
2022
Digital Research Alliance of Canada
2021
Psoriasis Association
2021
AbbVie (United States)
2021
Janssen (Belgium)
2021
Ferring Pharmaceuticals (Switzerland)
2021
Inflammatory bowel disease (IBD) represents a group of idiopathic, chronic, inflammatory intestinal conditions. Its two main categories are: Crohn's (CD) and ulcerative colitis (UC), which feature both overlapping distinct clinical pathological features. While these diseases have, in the past, been most evident developed world, their prevalence developing world has gradually increasing recent decades. This poses unique issues diagnosis management have scarcely addressed literature or extant...
The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory bowel diseases (IBDs). overall objective was to better understand and explore primary non response loss of agents IBD. outcome this is presented into two parts. This section addresses definitions, frequency pharmacological aspects failure, including pharmacokinetics monoclonal antibodies immune non-immune mediated clearance mAbs. second concerns the biological roles TNF antagonists, mechanisms action...
We sought to evaluate COVID-19 clinical course in patients with IBD treated different medication classes and combinations.
The International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) is only global organization devoted to study and management inflammatory bowel diseases (IBDs), namely, Crohn's disease ulcerative colitis. Membership composed physician-scientists who have established expertise in these diseases. hosts an annual meeting a number working groups addressing issues epidemiology IBD, diet nutrition, development use treatments IBD. There are currently 89 members IOIBD representing...
Inflammatory bowel disease (IBD) is a group of idiopathic chronic inflammatory intestinal conditions. The 2 main categories are Crohn's (CD) and ulcerative colitis (UC), which have both overlapping distinct clinical pathologic features. pathogenesis IBD incompletely understood. Genetic environmental factors such as altered luminal bacteria enhanced permeability play role in the dysregulation immunity, leading to gastrointestinal injury. GLOBAL INCIDENCE/PREVALENCE In developed countries, UC...
<h3>Importance</h3> Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact COVID-19 among individuals with IMIDs who receiving TNF remains insufficiently understood. <h3>Objective</h3> To examine association between receipt inhibitor monotherapy and risk COVID-19–associated hospitalization or death compared other commonly immunomodulatory...
Research has shown that fecal biomarkers are useful to assess the activity of inflammatory bowel disease (IBD). The aim study is: evaluate efficacy lactoferrin and calprotectin as indicators activity.A total 78 patients presenting were evaluated. Blood tests, Crohn's Disease Activity Index (CDAI), Mayo (MDAI), Endoscopic Severity (CDEIS) used for clinical endoscopic evaluation. Two tests performed on samples, check levels lactoferrin. performance these markers detection inflammation with...
We report the findings and outputs of an international expert opinion process to develop a definition early Crohn's disease (CD) that could be used in future disease-modification trials. Nineteen experts on inflammatory bowel diseases held meeting discuss agree for CD The included literature searches relevant basic-science clinical evidence. A published preliminary was as basis development proposed discussed at meeting. participants then derived final definition, based best current...
Infections are a safety concern in patients with ulcerative colitis [UC]. Etrasimod is an oral, once daily [QD], selective sphingosine 1-phosphate [S1P]1,4,5 receptor modulator for the treatment of moderately to severely active UC. It leads and reversible lymphocyte sequestration partial peripheral count decrease. We report infection events from phase 3 ELEVATE programme.
Every May 29th the World Gastroenterology Organization (WGO) celebrates Digestive Health Day (WDHD) and initiates a worldwide public health campaign through its 110 national societies 50,000 members. Each year focuses on particular digestive disorder in order to increase general awareness of prevention therapy. 2010 is dedicated inflammatory bowel disease (IBD). Upon this occasion WGO IBD task force was compiled from leading international specialists researchers. The also included members...
Abstract Background The effectiveness of ustekinumab (UST) in the treatment Crohn’s disease (CD) has been demonstrated pivotal Phase 3 UNITI 1 and 2 IM-UNITI studies both anti-TNF-naïve anti-TNF-exposed patients. Given selective nature trial designs, real-world safety are warranted. We report our experience with UST a large, multicenter cohort Brazilian patients CD. Methods performed retrospective study including CD, predominantly biologically refractory who received UST. primary endpoint...
Abstract Background The GRAVITI study established the efficacy and safety of subcutaneous (SC) induction with guselkumab (GUS), a dual-acting IL-23p19 subunit inhibitor, in participants (pts) moderately to severely active Crohn’s disease (CD) through 48 weeks treatment.1 Here, we evaluated GUS SC subgroups based on baseline demographics concomitant CD-related medications. Methods Eligible pts had history inadequate response or intolerance oral corticosteroids, azathioprine (AZA),...
Abstract Background Patients (pts) with Crohn’s disease (CD) suffer from symptoms that impair health-related quality of life (HRQoL).1-3 The Phase 3 GRAVITI treat-through trial evaluated the efficacy and safety SC induction maintenance guselkumab (GUS), an interleukin (IL)-23 p19 subunit antagonist, in pts moderately to severely active CD who had demonstrated a history inadequate response or intolerance oral corticosteroids, AZA, 6-MP, MTX, biologics. Here we report HRQoL as measured by...
Abstract Background The GRAVITI study established the efficacy and safety of subcutaneous (SC) induction with guselkumab, a dual-acting IL-23p19 subunit inhibitor, in participants moderately to severely active Crohn’s disease through 48 weeks treatment.1 Here, we evaluated guselkumab SC subgroups based on baseline characteristics. Methods Eligible had history inadequate response or intolerance oral corticosteroids, azathioprine, 6-mercaptopurine, methotrexate, biologics (ie, TNF antagonists...
Abstract Background Guselkumab (GUS) is a dual-acting IL-23p19 subunit inhibitor that was efficacious in phase 3 trials (GALAXI 2/3) of pts with CD using IV induction and SC maintenance. We evaluated the efficacy safety GUS induction/maintenance GRAVITI, treat-through trial moderately to severely active CD. Methods Eligible had history inadequate response or intolerance oral corticosteroids, AZA, 6-MP, MTX, biologics (BIO-IR). Randomization stratified by baseline (BL) CDAI, SES-CD, BIO-IR...